Confirmation of guideline‐defined hepatitis C screening strategies within the ‘Check‐Up35+’ examination in the primary care setting

Screening strategies for undiagnosed infections are fundamental for hepatitis C virus (HCV) elimination. We previously investigated HCV prevalence and screening strategies in an urban primary care setting. IV drug abuse, blood transfusion before 1992, immigration, or elevated ALT were identified as risk factors in a post hoc analysis and diagnosed 83% of unknown HCV‐RNA‐positive cases by screening only 26% of the population.

[1]  C. Wiedermann,et al.  Challenges and experiences of general practitioners during the course of the Covid-19 pandemic: a northern Italian observational study—cross-sectional analysis and comparison of a two-time survey in primary care , 2022, Family practice.

[2]  F. Tacke,et al.  Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany , 2022, Journal of viral hepatitis.

[3]  I. Peytremann-Bridevaux,et al.  Early impact of the COVID-19 pandemic on in-person outpatient care utilisation: a rapid review , 2022, BMJ Open.

[4]  T. Berg,et al.  From Screening to Therapy: Anti-HCV Screening and Linkage to Care in a Network of General Practitioners and a Private Gastroenterology Practice , 2021, Pathogens.

[5]  T. Berg,et al.  The Practicability of the Xpert HCV Viral Load Fingerstick Point-of-Care Assay in Primary Care Settings , 2021, Viruses.

[6]  J. Lazarus,et al.  Evaluation of the Xpert HCV VL Fingerstick point-of-care assay and dried blood spot HCV-RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain. , 2020, The International journal on drug policy.

[7]  Stephen R. Spriggs,et al.  CDC Recommendations for Hepatitis C Screening Among Adults — United States, 2020 , 2020, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[8]  T. Reiberger,et al.  Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs—First real world data from Austria , 2020, PloS one.

[9]  H. Razavi,et al.  Global timing of hepatitis C virus elimination in high‐income countries , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[10]  M. Thursz,et al.  Time matters: Point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England. , 2019, The International journal on drug policy.

[11]  J. Ward,et al.  Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct‐Acting, Pangenotypic Treatment Regimens , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  M. Manns,et al.  [4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)]. , 2019, Zeitschrift fur Gastroenterologie.

[13]  T. Berg,et al.  Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting , 2018, European journal of gastroenterology & hepatology.

[14]  T. Berg,et al.  Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. , 2015, Journal of hepatology.

[15]  G. Esmat,et al.  The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm , 2014, Journal of viral hepatitis.

[16]  J. Hoebel,et al.  Social status and participation in health checks in men and women in Germany: results from the German Health Update (GEDA), 2009 and 2010. , 2013, Deutsches Arzteblatt international.

[17]  M. Manns,et al.  [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. , 2018, Zeitschrift fur Gastroenterologie.